Linkage and retention in care and the time to HIV viral suppression and viral rebound – New York City

Abstract

The success of antiretroviral therapy (ART) as treatment for the individual patient and as prevention requires the achievment and maintenance of human immunodeficiency virus (HIV) viral suppression. Linkage to and retention in care are required for access to ART. We describe the impact of care on viral suppression using routinely reported surveillance data. We included New York City residents ≥13 years of age, diagnosed with HIV/AIDS from 1 July 2005 to 30 June 2009 with a viral load (VL) or CD4 reported within six months of diagnosis and ≥1 VL reported from 1 July 2005 to 30 June 2011. To examine viral rebound, we restricted the analysis to those who achieved viral suppression and had a subsequent VL measure reported by 30 June 2011. Cox proportional hazards models were used to evaluate factors associated with time to viral suppression (VL ≤ 400 copies/mL) and rebound (VL > 1000 copies/mL). Initiation of care within three months of diagnosis (CD4/VL report within three months of diagnosis), female sex, and an initial CD4 < 350 (cells/mm³) at diagnosis significantly increased the likelihood of viral suppression. Irregular care (no CD4/VL reported every six months), younger age, non-white race/ethnicity, having an initial CD4 ≥ 350 at diagnosis, and AIDS diagnosis by 2010 increased the likelihood of rebound. These findings lend support to interventions for improving linkage to and maintenance in regular care as a way to achieve and maintain suppression. Surveillance data represent an ideal means for monitoring engagement in care and viral suppression at the population level.

Keywords:

• HIV viral suppression
• HIV viral rebound
• HIV viral load
• initiation of care
• linkage to care
• retention in care

Funding

This research supported in part by a cooperative agreement with the Centers for Disease Control and Prevention (CDC) [grant number PS08-80,202], [grant number UC62/CCU223595] and by the CDC/CSTE applied epidemiology fellowship program.

Additional information

Funding

Funding:This research supported in part by a cooperative agreement with the Centers for Disease Control and Prevention (CDC) [grant number PS08-80,202], [grant number UC62/CCU223595] and by the CDC/CSTE applied epidemiology fellowship program.